Compare KKR & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KKR | BMY |
|---|---|---|
| Founded | 1976 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.1B | 113.5B |
| IPO Year | 2007 | 2006 |
| Metric | KKR | BMY |
|---|---|---|
| Price | $108.67 | $64.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $132.85 | $61.73 |
| AVG Volume (30 Days) | 4.7M | ★ 11.8M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | 0.75% | ★ 4.38% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | $19,464,307,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.41 | N/A |
| P/E Ratio | $44.27 | ★ $21.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $82.67 | $42.52 |
| 52 Week High | $152.10 | $68.10 |
| Indicator | KKR | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 59.57 |
| Support Level | $98.65 | $56.46 |
| Resistance Level | $124.70 | $68.10 |
| Average True Range (ATR) | 4.34 | 1.75 |
| MACD | 0.80 | -0.24 |
| Stochastic Oscillator | 69.52 | 39.35 |
KKR is one of the world's largest alternative asset managers, with $723.2 billion in total managed assets, including $585.0 billion in fee-earning AUM, at the end of September 2025. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.